Sleep Disorders Trial, Recruiting NCT06156306 Sponsor: Chinese University of Hong Kong Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT06156306
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Chinese young people between 15 and 24 years old
  • People whose insomnia symptoms score 9 or above on a standard insomnia measurement scale (the Insomnia Severity Index)
  • People whose anxiety symptoms score 10 or above on a standard anxiety measurement scale (the General Anxiety Disorder-7 scale)
  • People who can listen, speak, and read Chinese and Cantonese
  • People who are able to provide written agreement to participate; for those under 18, a parent or guardian must also provide written consent, and the young person's own agreement is separately recorded
  • People who own a smartphone

Who may not be able to join:

  • People who have a diagnosed condition such as psychosis, schizophrenia, bipolar disorder, or intellectual disability
  • People who have a diagnosed sleep disorder (such as delayed sleep phase disorder or narcolepsy) that a clinical interview determines may be causing their sleep problems
  • People assessed as having significant suicidal thoughts that include a plan or a past attempt, as identified through a structured clinical interview
  • People who are currently receiving any talking therapy or medication treatment for insomnia or an anxiety disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rachel Ngan Yin Chan, PhD, Department of Psychiatry, the Chinese University of Hong Kong

Phone: 39710550

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 December 2023
Est. completion
15 December 2025

Where this trial is recruiting

Hong Kong

Primary endpoints

Severity of anxiety symptoms and severity; Severity of anxiety symptoms; Clinician-rated severity of anxiety symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov